¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high purified insulin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed core cut biopsy
    °í¼ÓÁ߽ɺλý°Ë
  • high temperature sterilization
    °í¿Â¸ê±Õ
  • high tone deafness
    °íÀ½³­Ã»
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °íÀü¾Ð¹æ»ç¼±ÃÔ¿µ(¼ú)
  • high zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-fiber diet
    °í¼¶À¯Áú½Ä»ç
  • high-grade
    °íµµ
  • high-grade squamous intraepithelial lesion
    °íµî±ÞÆíÆò»óÇdz»º´ÅÍ
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½É(Àå)ºÎÀü
  • high-pass filter
    °íÁÖÆÄÅë°ú¿©°ú±â, °íÁÖÆÄÅë°ú°Å¸£°³
  • high-performance liquid chromatography
    °í¼º´É¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-pressure liquid chromatography
    °í¾Ð¾×üũ·Î¸¶Åä±×·¡ÇÇ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high temperature sterilization
    °í¿Â¸ê±Õ
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
  • high-altitude illness
    °í¼ÒÁúº´
  • high-density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹é
  • high-dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • one step high level resistance
    ÀÏȸ°íÀúÇ×ȹµæ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high frequency jet ventilation =HFJV
    °íºóµµÁ¦Æ®È¯±â.
  • high frequency oscillation ventilation =HFOV
    °íºóµµÁøµ¿È¯±â
  • high frequency positive pressure ventilation =HFPPV
    °íºóµµ¾ç¾Ðȯ±â.
  • high frequency recombination (Hfr)
    °íºóµµÀçÁ¶ÇÕ
  • high frequency transducing lysate
    °íºóµµÇüÁúµµÀÔ ¿ë±Õ¹°
  • high frequency transduction
    °íºóµµÇüÁúµµÀÔ
  • high frequency ventilation = HFV
    °íºóµµÈ¯±â
  • high fusing porcelain
    °í¿ëµµÀç(ÍÔéÁÔ¶î§).
  • high insertion
    °íÀ§ºÎÂø
  • high lateral myocardial infarction
    È޾߼øÈ¯°íÀ§Ãøº®½É±Ù°æ»öÁõ(ÍÔêÈö°ÛúãýÐÉÌÛßáñø ).
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • high lithotomy
    °íÀ§Àý¼®¼ú(°íÀ§Ã¼¼®¼ú).
  • high molecular weight kinin
    °íºÐÀÚ·®Å°´Ñ
  • high molecular weight kininogen
    °íºÐÀÚÁß·®Å°´Ï³ë°Õ
  • high myopia
    °íµµ±Ù½Ã(ÍÔöôÐÎãÊ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • oral insulin substitute
    °æ±¸(Àû) ´ë¿ë(ÌèÏ¢(îÜ) ÓÛéÄ)Àν¶¸°, °æ±¸(Àû) Àν¶¸° ´ë¿ë¾à(¡­ÓÛéÄå·).
  • protamin insulin(e)
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) insulin
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • short acting insulin
    ¼ÓÈ¿¼º Àν¶¸°.
  • suppressive insulin
    ¾ïÁ¦Çü(åäð¤úþ)Àν¶¸°.
  • ultralente insulin
    ÃÊÁö¿¬¼º Àν¶¸°.
  • zinc insulin crystals
    ¾Æ¿¬Àν¶¸°°áÁ¤(¡­Ì¿ïÜ).
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
HEP hemolysis end point; hepatoerythropoietic porphyria; high egg passage [virus]; high-energy phosphate...
HFD hemorrhagic fever of deer; high-fiber diet; high forceps delivery; hospital field director; human fa...
HFHV high frequency, high volume
HFO high-frequency oscillator; high-frequency oscillatory [ventilation]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
GIT Glutathione-insulin trandhydrogenase
HI Human insulin
HIR Human insulin receptor
hIGF-I Human insulin-like growth factor I
IDDM I-insulin-dependent diabetes mellitus
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
insulin resistance Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range.
(09 Oct 1997)
insulin shock A severe condition that occurs when the level of blood glucose (sugar) drops quickly. The signs are shaking, sweating, dizziness, double vision, convulsions, and collapse. Insulin shock may occur when an insulin reaction is not treated quickly enough.
See: hypoglycaemia.
(09 Oct 1997)
insulin shock treatment Formerly used treatment for serious mental disorders in which the patient was given insulin to induce a seizure; supplanted by electroshock therapy.
(05 Mar 2000)
insulin-stimulating peptide <chemical> 71-amino acid containing peptide; corresponds to residues 115-143 and 144-184 of bovine serum albumin with the exception of a tyrosine insertion between residues 155 and 156; consists of two chains with mw 5000 and 3400 for each chain
Synonym: h-isp, insulin-stimulating protein
(05 Dec 1998)
insulin unit The activity contained in 1/22 mg of the international standard of zinc-insulin crystals.
(05 Mar 2000)
insulin zinc suspension A sterile buffered suspension with zinc chloride, containing 40 or 80 units per ml; the solid phase of the suspension consists of a mixture of 7 parts of crystalline insulin and 3 parts of amorphous insulin.
Synonym: lente insulin.
(05 Mar 2000)
extended insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
ultralente insulin A form of zinc precipitated insulin in suspension in which the particle size is large, and thus release into the bloodstream after subcutaneous injection is slow; it can be mixed with other insulins having different particle sizes to achieve different durations of activity. Can be derived from porcine, bovine, or genetically engineered human type.
(05 Mar 2000)
lente insulin A sterile buffered suspension with zinc chloride, containing 40 or 80 units per ml; the solid phase of the suspension consists of a mixture of 7 parts of crystalline insulin and 3 parts of amorphous insulin.
Synonym: lente insulin.
(05 Mar 2000)
blood pressure, high High blood pressure (hypertension) is a repeatedly elevated blood pressure exceeding 140 over 90 mmHg. High blood pressure is also called the silent killer. Chronically high blood pressure can cause blood vessel changes in the back of the eye (retina), thickening of the heart muscle, kidney failure, and brain damage. No specific cause for high blood pressure is found in 95% of patients. High blood pressure is treated with salt restriction, regular aerobic exercise, and medications.
(12 Dec 1998)
blood sugar, high Elevated levels of blood glucose (hyperglycaemia) can be found in a number of conditions. The hyperglycaemia leads to spillage of glucose into the urine, hence the term sweet urine. (Diabetes mellitus means sweet urine. )
(12 Dec 1998)
cardiac output, high A state of elevated cardiac output. Conditions that lower peripheral vascular resistance, such as anaemia, arteriovenous fistulas, thyrotoxicosis, and pregnancy, are among the most important factors augmenting the venous return and therefore elevating cardiac output. Increased cardiac output also occurs in muscular exercise, fever, and severe anoxia.
(12 Dec 1998)
radiotherapy, high-energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; X-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle.
(12 Dec 1998)
mean higher high water <marine biology> The average height of the higher high water over a 19-year period. For shorter periods of observation, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value.
(09 Oct 1997)
mean high water <marine biology> The average height of the high water over a 19-year period. For shorter periods of observation, corrections are applied to eliminate known variations and reduce the result to the equivalent of a mean 19-year value.
All high-waters heights are included in the average where the type of tide is either semidiurnal or mixed. Only the higher high-water heights are included in the average where the type of tide is diurnal. So determined, mean high water in the latter case is the same as mean higher high water.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • high living
    ȣȭ½º·¯¿î »ýȰ 
  • high noon
    Çѳ·;Á¤¿À
  • high pillow
    °Å¹°;Áß¿ä Àι°
  • high pitch
    (³ëÁ¡ »óÀÎÀÇ)ÆÇ¸Å´ë
  • high place
    »ê²À´ë±âÀÇ ¿¹¹è Àå¼Ò;Áß¿äÇÑ ÁöÀ§;¿äÁ÷;°í°ü
  • high pockets
    Ű´Ù¸®
  • high point
    Áß´ëÇÑ ½ÃÁ¡;ÃÖ°íÀÇ ½Ã±â
  • high polymer
    °íºÐÀÚ(°Å´ëºÐÀÚ) ¹°Áú
  • high polymer chemistry
    °íºÐÀÚ(È­)ÇÐÀÇ;°­·ÂÇÑ;(±¤ÇÐ ±â±â°¡)¹èÀ²ÀÌ ³ôÀº;Á¤·ÂÀûÀÎ
  • high priest
    Á¦»çÀå;(¿¾ À¯´ë±³ÀÇ)´ëÁ¦»çÀå;°í½Â;(ÁÖÀÇ,¿îµ¿ÀÇ)ÁöµµÀÚ
  • high profile
    ¸íÈ®ÇÑ Åµµ(Á¤Ã¥);¼±¸íÇÑ ÀÔÀå
  • high relief
    =alto relievo
  • high roller
    ³¶ºñÀÚ;³­ºÀ²Û;³ë¸§²Û
  • high school
    °íµîÇб³;ÁßµîÇб³
  • high schooler
    °íµî Çб³ Çлý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á